PubMed Health⌕ Search

PubMed · 11308485

Entropy-driven demixing in spherocylinder binary mixtures.

Abstract

The stability of binary fluid mixtures, with respect to a demixing transition, is examined within the framework of the geometrical approximation of the direct correlation for hard nonspherical particles. In this theory, the direct correlation function is essentially written in terms of the geometrical properties of the individual molecules, and those of the overlap region between two different molecules, taken at fixed separation and orientations. Within the present theory, the demixing spinodal line in the (rho(1),rho(2)) concentration plane is obtained analytically, and shown to be a quadratic function of the total packing fraction and the compositions. The theory is applied herein to binary mixtures of hard spherocylinders in the isotropic phase. Isotropic fluid-fluid demixing can be predicted for a large variety of sizes and aspect ratios, and the necessary condition for entropic demixing is a sufficiently large thickness difference between the two particles that belong to each of the fluids in the mixture. As the theory reduces exactly to the Percus-Yevick approximation for a hard sphere mixture, accordingly it will not predict fluid-fluid demixing for this particular case. Demixing is also forbidden in two other cases; for a mixture of spherocylinders and small spheres, and for mixtures of equally thin spherocylinders. The influence and competition of an ordering instability on the demixing is also examined. The ordering of a fluid will always be displaced toward higher packing fractions by the addition of a nonordering fluid, and in some cases the entropic demixing can dominate the entire fluid range. Although the present theory merges exactly with the correct Onsager limit, it is shown that, for intermediate cases, the results can be significantly different from predictions of Onsager type approaches. These discrepancies are analyzed in particular for the needle plus spherocylinder mixture. Finally, in view of the nature of the theory, it is conjectured that the predicted demixing densities values are rather upper bounds to what should be expected.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H Bosetti, A Perera. 2001-01-26. Entropy-driven demixing in spherocylinder binary mixtures.. https://doi.org/10.1103/physreve.63.021206

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗